185 related articles for article (PubMed ID: 38032827)
21. [Current aspects of the treatment of urogenital atrophy (based on the consensus of britain society of menopause)].
Balan VE; Tikhomirova EV; Tsarkova AV; Gadgieva ZK
Urologiia; 2019 Dec; (5):150-154. PubMed ID: 31808652
[TBL] [Abstract][Full Text] [Related]
22. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
J Sex Med; 2014 Dec; 11(12):2865-72. PubMed ID: 25155380
[TBL] [Abstract][Full Text] [Related]
23. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia.
Wallace SL; St Martin B; Lee K; Sokol ER
Am J Obstet Gynecol; 2020 Dec; 223(6):890.e1-890.e12. PubMed ID: 32562659
[TBL] [Abstract][Full Text] [Related]
24. Assessment of ospemifene or lubricants on clinical signs of VVA.
Constantine G; Graham S; Koltun WD; Kingsberg SA
J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
[TBL] [Abstract][Full Text] [Related]
25. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
[TBL] [Abstract][Full Text] [Related]
26. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
27. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
28. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
Maturitas; 2014 Nov; 79(3):349-54. PubMed ID: 25179577
[TBL] [Abstract][Full Text] [Related]
29. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause.
Cox P; Panay N
Climacteric; 2023 Aug; 26(4):367-372. PubMed ID: 37199295
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
31. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
[TBL] [Abstract][Full Text] [Related]
32. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.
Constantine G; Graham S; Portman DJ; Rosen RC; Kingsberg SA
Climacteric; 2015 Apr; 18(2):226-32. PubMed ID: 25252699
[TBL] [Abstract][Full Text] [Related]
33. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy.
Pérez-López FR; Vieira-Baptista P; Phillips N; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):740-745. PubMed ID: 34036849
[TBL] [Abstract][Full Text] [Related]
34. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
Archer DF; Simon JA; Portman DJ; Goldstein SR; Goldstein I
Expert Rev Endocrinol Metab; 2019 Sep; 14(5):301-314. PubMed ID: 31526199
[No Abstract] [Full Text] [Related]
35. Genitourinary syndrome of menopause and the use of laser therapy.
Hutchinson-Colas J; Segal S
Maturitas; 2015 Dec; 82(4):342-5. PubMed ID: 26323234
[TBL] [Abstract][Full Text] [Related]
36. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
37. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.
Palma F; Volpe A; Villa P; Cagnacci A;
Maturitas; 2016 Jan; 83():40-4. PubMed ID: 26421474
[TBL] [Abstract][Full Text] [Related]
38. Ospemifene: a safe treatment of vaginal atrophy.
Del Pup L
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(18):3934-3944. PubMed ID: 27735020
[TBL] [Abstract][Full Text] [Related]
39. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial.
Bumphenkiatikul T; Panyakhamlerd K; Chatsuwan T; Ariyasriwatana C; Suwan A; Taweepolcharoen C; Taechakraichana N
BMC Womens Health; 2020 Aug; 20(1):173. PubMed ID: 32787848
[TBL] [Abstract][Full Text] [Related]
40. [How I do? a treatment with fractional CO
Jardin I; Louis-Vahdat C; Canlorbe G; Mergui JL; Uzan C; Azaïs H
Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):735-739. PubMed ID: 30266539
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
